Evommune (EVMN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Meeting commenced at 11:30 A.M. ET on June 2, 2026, via a virtual platform, with recording available for 30 days.
Board members, executive officers, auditors, and legal counsel were introduced at the start.
The agenda included two proposals: election of directors and ratification of the independent auditor.
Shareholder proposals
Two proposals were presented: election of two Class 1 directors to serve until 2029, and ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Q&A with stakeholders
Shareholders could submit questions online during the meeting, but no questions were received.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Evommune
- Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum.EVMN
Corporate presentation - Net loss rose to $53.9 million as expenses increased, but cash runway extends through 2028.EVMNQ2 2026
- Advancing novel oral and biologic therapies for inflammation with strong clinical and financial momentum.EVMNCorporate presentation
- Net loss widened to $21.7 million in Q1 2026, with cash runway extended through 2028.EVMNQ1 2026
- Director elections and auditor ratification headline the June 2026 virtual annual meeting.EVMNProxy filing
- Shareholders will vote on director elections and auditor ratification, with strong governance and ESG oversight.EVMNProxy filing
- Biotech enables resale of 4.5M shares post-IPO, advancing inflammation therapies amid sector risks.EVMNRegistration filing
- EVO756 phase IIb trial targets migraine prevention with a novel oral MRGPRX2 antagonist.EVMNStatus update
- EVO301 showed rapid, significant efficacy and safety in phase 2A atopic dermatitis, enabling phase 2B plans.EVMNStudy result